Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.82 |
| ▸ | P4HB | P07237 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965590 | 0.93 | MDM2 (0.82) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965770 | 0.92 | MDM2 (0.89) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965631 | 0.92 | MDM2 (0.89) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL15781896 | 0.92 | MDM2 (0.76) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965518 | 0.91 | MDM2 (0.80) | MDM2P4HBTP53MAPT | |
| SCHEMBL9965765 | 0.91 | MDM2 (0.72) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965552 | 0.90 | MDM2 (0.77) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965508 | 0.90 | MDM2 (1.00) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965506 | 0.89 | MDM2 (0.73) | MDM2P4HBKMT2ARAB9ANPC1 | |
| SCHEMBL9965704 | 0.88 | MDM2 (0.73) | MDM2P4HBKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9023354-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO, JOSEPH P. | 2015-04-16 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | MDM2 3/4885P4HB 4025/4885KMT2A 3490/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | MDM2 448/4885P4HB 2320/4885KMT2A 3667/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | MDM2 354/4885P4HB 2500/4885KMT2A 3952/4885 |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | MDM2 3/4885P4HB 4025/4885KMT2A 3490/4885 |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | MDM2 3/4885P4HB 4025/4885KMT2A 3490/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | MDM2 288/4885P4HB 2095/4885KMT2A 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.